Viruses Against Bacteria: Development of Novel Therapeutics Boosted With Millions of Euros

August 28, 2018
PhagoMed Biopharma GmbH

Vienna, 28 August 2018: The development of alternative therapies to combat antibiotic-resistant bacteria has attracted more than €4 million in grants and private investments for Vienna-based biotech company PhagoMed Biopharma GmbH (PhagoMed). PhagoMed, located at the Vienna Biocenter, is focused on developing virus–(phage–) based therapies against bacterial infections. The financing will be used to continue the pre-clinical development of three drug candidates.

More info on: